Merck acquires cancer play Rigontec

Merck & Co. Inc. (NYSE:MRK) is acquiring immuno-oncology company Rigontec GmbH (Munich, Germany). Rigontec will receive €115 million ($136.8 million) in cash up front and is eligible for up to €349 million ($415.2 million) in milestones. The deal is expected to close in about four weeks.

Rigontec raised €29.3 million ($32.7 million) in a tranched series A, which closed about a year ago (see BioCentury, Sept. 12, 2016)...